Skip to main content

Health policy or intellectual property policy? The fight over Bill C-91

Buy Article:

$46.75 plus tax (Refund Policy)

Adapted from the Canadian Healthcare Association's submission to the House of Commons Standing Committee on Industry currently reviewing Bill C-91, an Act to amend the Patent Act. Discusses the controversy surrounding this legislation, which extended patent protection to brand-name drug manufacturers to 20 years before generic copies of pharmaceuticals can be introduced on to the market.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Data/Media
No Metrics

Keywords: Canada; Patients; Pharmaceutical industry

Document Type: Research Article

Publication date: 1997-04-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more